熱門資訊> 正文
Inozymy Pharma GAAP每股收益为-0.44美元
2024-08-06 21:29
- Inozyme Pharma press release (NASDAQ:INZY): Q2 GAAP EPS of -$0.44.
- Cash, cash equivalents, and short-term investments were $144.5 million as of June 30, 2024.
-
More on Inozyme Pharma
- Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
- Inozyme gets Fast Track status for candidate for rare calcification condition
- Seeking Alpha’s Quant Rating on Inozyme Pharma
- Historical earnings data for Inozyme Pharma
- Financial information for Inozyme Pharma
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。